The BioMedomics COVID-19 IgG/IgM Rapid Test is a rapid, point-of-care (POC) lateral flow immunoassay (LFA) that detects antibodies to the SARS-CoV-2 spike protein receptor-binding domain
BioMedomics, Inc. is proud to announce that the BSI Group of America has accredited and recertified our ISO 13485:2016 certification. The certification of compliance with
Article about BioMedomics’s COVID-19 IgM/IgG Rapid Antibody Test Awarded as Top Cited Paper in Journal of Medical Virology!
An article about BioMedomics’s COVID-19 IgM/IgG Rapid Antibody Test that several employees of BioMedomics, Inc., worked on has been awarded as one of the top
BioMedomics, Inc. is proud to announce its ISO 13485:2016 certificate has expanded in scope to include the design, development and manufacturing of COVID-19 rapid tests.
We are excited to announce that the National Institute for Food and Drug Surveillance (INVIMA) has given BioMedomics, Inc. authorization to sell and distribute our
We are excited to announce that the Therapeutic Goods Administration, a branch of the Department of Health in the Australian Government, has given BioMedomics, Inc.
We are excited to announce that the Tanzania Medicines and Medical Devices Authority has given authorization to BioMedomics, Inc. to sell and distribute our world-renown
BioMedomics is the first company to publish a journal article about the development and launch of a rapid COVID-19 test. You can also refer to
BioMedomics™ Participates in Free Sickle Cell Screening Events Using Sickle SCAN® Rapid Test During MEA Rugby Championship
Morrisville, NC, USA – BioMedomics, a leader in innovative clinical diagnostics products that address global healthcare needs, participated in several sickle cell screening events in